ARCAMYRA THERAPEUTICS · BROWN UNIVERSITY HEALTH

FOR IMMEDIATE RELEASE

Brown University Health and Arcamyra Therapeutics Announce First Patient Dosed in Phase 1 Trial of ACM-CpG for Peritoneal Carcinomatosis

First patient treated in the investigator-initiated BrUOG 452 study (NCT07658196) of ACM-CpG, a polymersome-encapsulated TLR9 agonist administered intraperitoneally

PROVIDENCE, R.I., October 27, 2026 — Brown University Health and Arcamyra Therapeutics, Inc., a clinical-stage oncology company developing nanoparticle-based immunotherapies for cancers with high unmet need, today announced that the first patient has been dosed in BrUOG 452 (ClinicalTrials.gov Identifier: NCT07658196), a Phase 1 investigator-initiated trial of ACM-CpG in patients with peritoneal carcinomatosis.

BrUOG 452 is conducted by the Brown University Oncology Research Group (BrUOG) and led by Khaldoun Almhanna, M.D., at Brown University Health and The Warren Alpert Medical School of Brown University. The trial follows FDA clearance of Arcamyra's Investigational New Drug application (IND 180703) earlier this year and is the first clinical evaluation of ACM-CpG in peritoneal carcinomatosis. The study uses an adaptive dose-escalation design and is enrolling patients with peritoneal carcinomatosis arising from colorectal or appendiceal cancer.

Peritoneal carcinomatosis — the spread of cancer to the peritoneum, the membrane lining the abdominal cavity — is an advanced manifestation of several gastrointestinal cancers. It carries a poor prognosis and limited treatment options, representing a long-standing area of high unmet medical need.

ACM-CpG is a polymersome-encapsulated TLR9 (Toll-like receptor 9) agonist built on Arcamyra's proprietary block-copolymer nanoparticle platform, which enhances immune cell uptake in solid tumor patients via different routes of administration to support robust pipeline growth. In BrUOG 452, ACM-CpG is administered intraperitoneally to induce innate-immune activation regionally within the peritoneal cavity. In earlier clinical evaluations in other indications, ACM-CpG has been well tolerated and has shown evidence of targeted immune activation.

"Dosing the first patient moves ACM-CpG from regulatory clearance into active clinical evaluation — a meaningful step for Arcamyra and, above all, for patients with peritoneal carcinomatosis, who have few effective options today," said Madhavan Nallani, Ph.D., Chief Executive Officer and Founder of Arcamyra Therapeutics. "We are grateful to Dr. Almhanna and the BrUOG team at Brown, and we look forward to advancing ACM-CpG across our pipeline."

"Reaching the first dose in BrUOG 452 is an important milestone for our patients," said Khaldoun Almhanna, M.D. "ACM-CpG's early tolerability and immune-activation profile in other settings provide a strong rationale for studying this regional immunotherapy in peritoneal disease, and we are pleased to begin treating patients."

About ACM-CpG

ACM-CpG is Arcamyra's lead investigational candidate: a polymersome-encapsulated TLR9 agonist developed on the company's proprietary block-copolymer nanoparticle platform. It is being studied across multiple tumor types and routes of administration. ACM-CpG is an investigational agent and has not been approved by the FDA or any other regulatory authority for any use.

About Arcamyra Therapeutics

Arcamyra Therapeutics, Inc. is a clinical-stage oncology company developing nanoparticle-based immunotherapies for cancers with high unmet need. The company's lead program targets peritoneal carcinomatosis. For more information, visit https://arcamyra.com/.

About Brown University Health

Brown University Health is a not-for-profit health system based in Providence, R.I., formed in 1994, and is comprised of three teaching hospitals of The Warren Alpert Medical School of Brown University: Rhode Island Hospital and its Hasbro Children's Hospital; The Miriam Hospital; and Bradley Hospital, the nation's first psychiatric hospital for children. It also includes Newport Hospital, Saint Anne's Hospital, and Morton Hospital, which offer a broad range of health services; Gateway Healthcare, R.I.'s largest provider of community behavioral health care; Brown Health Medical Group, the largest multi-specialty practice in R.I.; and Brown Health Medical Group Primary Care, a primary care-driven medical practice. Brown University Health teaching hospitals are among the country's top recipients of research funding from the National Institutes of Health. All Brown University Health-affiliated partners are charitable organizations that depend on support from the community to provide programs and services.

Media & Investor Contacts

Arcamyra Therapeutics
Peter Moran, Head of Corporate Affairs
peter.moran@acmbiolabs.com | +65 6265 5646

Brown University Health
Jessica Wharton
Senior Public Relations and External Affairs Strategist
jwharton@brownhealth.com | 401.525.8928

Brown University
Kris Cambra, Assistant Dean of Biomedical Communications
Kris_cambra@brown.edu | 401-332-9362

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the initiation, timing, conduct, and potential of Arcamyra's clinical program for ACM-CpG. These statements are based on current expectations and are subject to risks and uncertainties, including those related to clinical development, regulatory review, patient enrollment, and the inherent uncertainty of the drug development process. Clearance of an IND does not guarantee that a clinical trial will be initiated, completed, or successful, or that any product candidate will receive marketing approval. Actual results may differ materially from those expressed or implied. Arcamyra undertakes no obligation to update any forward-looking statement except as required by law.

###